Quinoline sulfonyl derivatives and uses thereof

1. A compound, wherein the compound is:

7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline,

methyl 3-(4-(7-chloroquinolin-4-yl)piperazin-1-ylsulfonyl)thiophene-2-carboxylate,

7-chloro-4-(4-(biphenylsulfonyl)piperazin-1-yl)quinoline,

5-(4-(7-chloroquinolin-4-yl)piperazin-1-ylsulfonyl)-N,N-dimethylnaphthalen-1-amine,

7-chloro-4-(4-(2,4-dichlorophenylsulfonyl)piperazin-1-yl)quinoline,

4-[4-(3-nitro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoline,

4-[4-(4-chloro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoline,

4-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoline,

4-[4-(biphenyl-4-sulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoline,

4-[4-(2,4-dichloro-benzenesulfony)-piperazin-1-yl]-7-trifluoromethyl-quinoline,

4-(4-methanesufonyl-piperazin-1-yl)-7-trifluoromethyl-quinoline,

4-[4-(2,4-dinitro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethyl-quinoline,

dimethyl-{5-[4-(7-trifluoromethyl-quinolin-4-yl)piperazine-1-sulfonyl]-naphthalen-1-yl}-amine, or

3-[4-(7-trifluoromethyl-quinolin-4-yl)-piperazine-1-sulfonyl]thiophene-2-carboxylic acid methyl ester,

or a pharmaceutically acceptable salt or solvate thereof.

2. A pharmaceutical composition comprising one or more compounds according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

3. A method of treating a subject with cancer, the method comprising administering a compound, or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 or a pharmaceutical composition as defined in claim 2 , to the subject, wherein the cancer is breast cancer, lymphoma, cervical cancer or brain cancer.

4. The method according to claim 3 , wherein the compound or pharmaceutically acceptable salt thereof or the pharmaceutical composition is administered to the subject in combination with an anti-cancer agent.

5. The method according to claim 4 , wherein the anti-cancer agent is selected from Bortezomib, paclitaxel, Monastrol, Vinca , VX-680, ZM447439, Hesperidin, temozolomide, Nocodazole, Bevacizumab, Cetuximab, Geftinib, Trastuzumab, Tipifarnib, CCI-779, Ly294002, Sunitinib maleate, API-1, and Akt1/2 inhibitor.

6. The method according to claim 3 , wherein the subject is a human.

7. The compound according to claim 1 , wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof.

8. The pharmaceutical composition according to claim 2 , wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof.

9. The method according to claim 3 , wherein the method comprises administering 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof to the subject.

10. The method according to claim 4 , wherein the anti-cancer agent is ionizing radiation.

11. The compound according to claim 1 , wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline.

12. The pharmaceutical composition according to claim 2 , wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline.

13. The method according to claim 9 , wherein the method comprises administering 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline to the subject.

14. The method according to claim 13 , wherein the compound is administered to the subject in combination with an anti-cancer agent.

15. The method according to claim 5 , wherein the anti-cancer agent is paclitaxel or bortezomib.

16. The method according to claim 14 , wherein the anti-cancer agent is paclitaxel or bortezomib.

17. The method according to claim 15 , wherein the cancer is breast cancer.